WO2010103959A1 - 慢性閉塞性肺疾患改善剤 - Google Patents
慢性閉塞性肺疾患改善剤 Download PDFInfo
- Publication number
- WO2010103959A1 WO2010103959A1 PCT/JP2010/053317 JP2010053317W WO2010103959A1 WO 2010103959 A1 WO2010103959 A1 WO 2010103959A1 JP 2010053317 W JP2010053317 W JP 2010053317W WO 2010103959 A1 WO2010103959 A1 WO 2010103959A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sod
- agent
- obstructive pulmonary
- pulmonary disease
- chronic obstructive
- Prior art date
Links
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 title claims abstract description 65
- 102000019197 Superoxide Dismutase Human genes 0.000 claims abstract description 69
- 108010012715 Superoxide dismutase Proteins 0.000 claims abstract description 69
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 45
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 16
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 14
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000004480 active ingredient Substances 0.000 claims abstract description 12
- 108010074060 lecithinized superoxide dismutase Proteins 0.000 claims abstract description 11
- 239000000126 substance Substances 0.000 claims abstract description 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 5
- 239000010949 copper Substances 0.000 claims description 20
- 229930006000 Sucrose Natural products 0.000 claims description 18
- 239000005720 sucrose Substances 0.000 claims description 18
- 239000011701 zinc Substances 0.000 claims description 18
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 17
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical class [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 claims description 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 8
- 239000003381 stabilizer Substances 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- 235000001014 amino acid Nutrition 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 3
- 229910052802 copper Inorganic materials 0.000 claims description 3
- 229940124597 therapeutic agent Drugs 0.000 claims description 3
- 229910052725 zinc Inorganic materials 0.000 claims description 3
- YPUBRSXDQSFQBA-BYPYZUCNSA-N 3-[(2-hydroxyethyl)disulfanyl]-L-alanine Chemical group OC(=O)[C@@H](N)CSSCCO YPUBRSXDQSFQBA-BYPYZUCNSA-N 0.000 claims description 2
- 125000000185 sucrose group Chemical group 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 16
- 239000001301 oxygen Substances 0.000 description 16
- 229910052760 oxygen Inorganic materials 0.000 description 16
- 238000002360 preparation method Methods 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 12
- 210000004969 inflammatory cell Anatomy 0.000 description 12
- 210000004072 lung Anatomy 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 210000000170 cell membrane Anatomy 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 239000000787 lecithin Substances 0.000 description 5
- 235000010445 lecithin Nutrition 0.000 description 5
- 229940067606 lecithin Drugs 0.000 description 5
- 210000000440 neutrophil Anatomy 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 108090000371 Esterases Proteins 0.000 description 4
- 208000004852 Lung Injury Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 102000016387 Pancreatic elastase Human genes 0.000 description 4
- 108010067372 Pancreatic elastase Proteins 0.000 description 4
- 206010069363 Traumatic lung injury Diseases 0.000 description 4
- 210000001132 alveolar macrophage Anatomy 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 210000000621 bronchi Anatomy 0.000 description 4
- 231100000515 lung injury Toxicity 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 239000006199 nebulizer Substances 0.000 description 4
- 210000002345 respiratory system Anatomy 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- -1 and specifically Proteins 0.000 description 3
- 229960000686 benzalkonium chloride Drugs 0.000 description 3
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 3
- 206010006451 bronchitis Diseases 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 238000010382 chemical cross-linking Methods 0.000 description 3
- 208000037976 chronic inflammation Diseases 0.000 description 3
- 230000006020 chronic inflammation Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 150000004665 fatty acids Chemical group 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 229940041682 inhalant solution Drugs 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 125000005471 saturated fatty acid group Chemical group 0.000 description 3
- 230000000391 smoking effect Effects 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- 206010006458 Bronchitis chronic Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010014561 Emphysema Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 208000007451 chronic bronchitis Diseases 0.000 description 2
- 230000007012 clinical effect Effects 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 238000001493 electron microscopy Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010007556 Cardiac failure acute Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- 208000005777 Lupus Nephritis Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000011623 Obstructive Lung disease Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 108010021188 Superoxide Dismutase-1 Proteins 0.000 description 1
- 102000008221 Superoxide Dismutase-1 Human genes 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003510 anti-fibrotic effect Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 125000001124 arachidoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000003910 behenoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 229950008138 carmellose Drugs 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 125000001142 dicarboxylic acid group Chemical group 0.000 description 1
- UMNKXPULIDJLSU-UHFFFAOYSA-N dichlorofluoromethane Chemical compound FC(Cl)Cl UMNKXPULIDJLSU-UHFFFAOYSA-N 0.000 description 1
- 229940099364 dichlorofluoromethane Drugs 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 229940066493 expectorants Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 238000003905 indoor air pollution Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 150000002505 iron Chemical class 0.000 description 1
- 150000004698 iron complex Chemical class 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 125000001419 myristoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 238000002640 oxygen therapy Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 230000005586 smoking cessation Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 125000005314 unsaturated fatty acid group Chemical group 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A61K47/544—Phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
- A61K38/446—Superoxide dismutase (1.15)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Definitions
- the present invention relates to an agent for improving chronic obstructive pulmonary disease, and in particular, to an agent for improving chronic obstructive pulmonary disease comprising lecithinized superoxide dismutase (hereinafter sometimes simply referred to as PC-SOD) as an active ingredient.
- PC-SOD lecithinized superoxide dismutase
- Superoxide dismutase (hereinafter sometimes referred to simply as SOD) was extracted as an anti-inflammatory protein from bovine blood by Huber et al. In 1965, and is specific to superoxide anion (O 2 ⁇ ), which is one of the active oxygens. It is a bioactive protein that has been clarified to be erased. In vivo, active oxygen is mainly released from phagocytic cells such as neutrophils and macrophages for sterilization, but there are usually various antioxidants such as SOD against surplus active oxygen. And protects normal cells from being damaged by active oxygen.
- PC-SOD Cu / Zn-human superoxide dismutase
- Acute heart failure treatment agent (patent document 2), antiviral agent (patent document 3), lupus nephritis treatment agent (patent document 4), which has already been recognized and containing PC-SOD as an active ingredient, and a function associated with cerebrovascular disorder Disability improving agent (patent document 5), antifibrotic agent (patent document 6) or antiallergic disease treating agent (patent document 7), burn therapeutic agent (patent document 8), interstitial pneumonia therapeutic agent (patent document 10) Various proposals have been made.
- COPD chronic obstructive pulmonary disease
- Non-Patent Document 1 The biggest cause of COPD is smoking. 90% of COPD patients are smokers (Non-Patent Document 1), and the risk of developing COPD is 6 times or more in smokers compared to non-smokers. About 10-15% of smokers develop COPD, but nearly 50% of them are COPD when limited to older people. Other causes include indoor air pollution, air pollution, inhalation of chemicals and dust, inheritance, and childhood pneumonia and bronchitis.
- the pathological condition is a disease characterized by airflow limitation, ie, difficulty in breathing, but the essence of the pathological condition is chronic inflammation of the respiratory tract. Smoking and inhalation substances cause inflammation at various levels of the lungs from the central airways to the peripheral bronchi. As a result, it is considered that alveolar destruction and bronchial mucus gland enlargement occur due to non-uniformity of protease / antiprotease and non-uniformity of oxidant / antioxidant.
- This COPD is a disease that cannot be cured because of irreversible airway destruction. It is a very troublesome disease because symptom relief is merely performed by smoking cessation, drug therapy by administration of bronchodilators, expectorants, antitussives, and oxygen therapy.
- the present inventor has examined the application of the previously proposed high-cytophilic lecithinized superoxide dismutase (PC-SOD) to COPD based on this concept. The present invention was completed by confirming that it was extremely effective in improving the symptom.
- PC-SOD high-cytophilic lecithinized superoxide dismutase
- an object of the present invention is to provide a safe and effective COPD improving agent containing PC-SOD as an active ingredient.
- the present invention for solving such a problem, as its basic aspect, The following general formula (I): SOD '(QB) m (I) (In the formula, SOD ′ represents a residue of superoxide dismutase, Q represents a chemical bridge, B represents a residue of lysolecithin having a hydroxyl group at the 2-position of glycerol excluding a hydrogen atom of the hydroxyl group, m Is the average binding number of lysolecithin to one molecule of superoxide dismutase, and represents an integer of 1 or more)
- the COPD improving agent characterized by using the lecithinized superoxide dismutase represented by these as an active ingredient.
- Q is —C (O) — (CH 2 ) n —C (O) — (wherein n is 2 or more) It is a COPD improving agent characterized by that.
- SOD ′ is a residue of human superoxide dismutase, and specifically, SOD ′ is an amino acid at position 111 in the amino acid sequence of human superoxide dismutase. It is a COPD improving agent characterized by being a residue of a modified superoxide dismutase converted to 2-hydroxyethylthio) cysteine.
- the present invention is a COPD improving agent characterized in that the superoxide dismutase is a superoxide dismutase containing copper and zinc at the active center.
- the present invention is a COPD improving agent containing a stabilizer along with lecithinized superoxide dismutase, and a COPD improving agent containing a sugar component, particularly sucrose as a stabilizing agent.
- the present invention is a COPD improving agent characterized by being in the form of an injection or inhalant.
- the present invention is a disease in which chronic inflammation occurs in the respiratory tract from the central bronchus to the peripheral orbit as the onset of COPD, and its induction involves active oxygen such as superoxide anion and iron complexes. Such induction can be effectively suppressed by eliminating such active oxygen, and as a result, effective improvement treatment of COPD can be performed.
- active oxygen such as superoxide anion and iron complexes.
- the PC-SOD used in the present invention has an excellent affinity for the cell membrane as compared with the conventional SOD, and has a high ability to eliminate the superoxide anion at the lesion site.
- a sugar component especially sucrose, as a stabilizer
- the stability of the PC-SOD itself is improved, the effect of SOD with a short half-life is continuously exhibited, and COPD is improved. It is particularly excellent in that it can be performed.
- lecithin means normal lecithin meaning phosphatidylcholine
- lysolecithin means glycerol of lecithin
- the PC-SOD used in the present invention can be usually obtained by binding one or more lecithin derivatives in which a chemical crosslinking agent is bonded to the hydroxyl group at the 2-position of lysolecithin to SOD.
- This PC-SOD has the following formula (I): SOD '(QB) m (I) (In the formula, SOD ′ represents a residue of superoxide dismutase, Q represents a chemical bridge, B represents a residue of lysolecithin having a hydroxyl group at the 2-position of glycerol excluding a hydrogen atom of the hydroxyl group, m Is the average binding number of lysolecithin to one molecule of superoxide dismutase, and represents an integer of 1 or more) Can be expressed as
- the SOD ′ used here is not particularly limited as long as it can exert its original function of decomposing active oxygen (O 2 ⁇ ) in the living body, and it is derived from various animals and plants or microorganisms. SOD residues can be widely used. However, when considering the use as a pharmaceutical, it is preferable to reduce antigenicity in vivo as much as possible. Therefore, it is preferable to select an appropriate SOD residue as the SOD ′ to be used depending on the subject to which the COPD improving agent of the present invention is administered.
- human-derived SOD is preferably used in consideration of antigenicity.
- human-derived Cu / Zn SOD human-derived SOD containing copper and zinc in the active center; hereinafter sometimes abbreviated as human Cu / Zn SOD
- human Cu / Zn SOD has an expression level in cells. Since many and production techniques by genetic engineering techniques have already been established and it can be prepared in large quantities, it is particularly preferably used.
- This human Cu / Zn SOD includes natural human Cu / Zn SOD produced from human tissue or cultured cells; human Cu / Zn SOD produced by genetic engineering techniques; substantially equivalent to natural human Cu / Zn SOD Recombinant human Cu / Zn SOD having the same amino acid sequence; SOD etc. in which some amino acids in the amino acid sequence in these human Cu / Zn SOD are deleted, added, substituted, or chemically modified or modified Any human Cu / Zn-SOD may be used.
- human Cu / Zn SOD in which the amino acid at position 111 (cysteine: Cys) in the amino acid sequence of natural human Cu / Zn SOD is S- (2-hydroxyethylthio) cysteine is preferable.
- the details of such human Cu / Zn SOD are described in, for example, JP-A-9-117279, and can be obtained according to the method. Therefore, the preparation of human Cu / Zn SOD described in JP-A-9-117279 constitutes a part of the present specification, and the PC-SOD used in the present invention uses these human Cu / Zn SODs. It can be obtained as a material.
- the “residue excluding the hydrogen atom of the hydroxyl group in lysolecithin having a hydroxyl group at the 2-position of glycerol” represented by B is specifically: Formula (II): —O—CH (CH 2 OR) [CH 2 OP (O) (O ⁇ ) (OCH 2 CH 2 N + (CH 3 ) 3 )] (II) (Wherein R is a fatty acid residue (acyl group)) It is represented by
- the fatty acid residue (acyl group) represented by R is preferably a saturated or unsaturated fatty acid residue having 10 to 28 carbon atoms, more preferably a myristoyl group, palmitoyl group, stearoyl group, icosanoyl group, docosanoyl group, and the like.
- the chemical crosslinking represented by Q in the general formula (I) is not particularly limited as long as it can chemically bond (covalently bond) SOD and lecithin by crosslinking.
- a residue: —C (O) — (CH 2 ) n —C (O) — (wherein n represents an integer of 2 or more) is particularly preferred.
- This residue has the formula: HO-C (O) - (CH 2) n -C (O) linear dicarboxylic acid represented by -OH, anhydrides, esters, present across such halides It is a residue excluding the hydroxyl group (in the case of an anhydride, ester, or halide, the portion corresponding to the hydroxyl group present at both ends).
- n is an integer of 2 or more, preferably an integer of 2 to 10.
- m represents the average number of lysolecithin bonds to SOD1 molecule. Accordingly, m is an integer of 1 or more, preferably 1 to 12, particularly 4.
- the method for producing PC-SOD used in the present invention that is, the method for binding lecithin derivatives and SOD, preferably human Cu / Zn SOD, can be carried out, for example, by the method described in JP-A-9-117279.
- PC-SOD is particularly preferable when the chemical structure of the preferred PC-SOD is schematically shown.
- an average of 4 molecules of lecithin derivatives are covalently bonded to the free amino group of human Cu / Zn SOD produced by genetic recombination using E. coli as a host.
- the PC-SOD used in the COPD improving agent of the present invention is preferably purified to such an extent that it can be used as a medicament and substantially free from substances that are not allowed to be mixed as a medicament.
- a purified PC-SOD having a specific SOD activity of 2,500 U / mg or more, and more preferably a purified one having a specific SOD activity of 3,000 U / mg or more.
- 1 U unit refers to J. Biol. Chem., Vol. 244, No. 22 6049-6055 (1969) using NBT (nitroblue tetrazolium) under the condition of pH 7.8 / 30 ° C. )
- NBT nitrogenblue tetrazolium
- the COPD improving agent provided by the present invention is a COPD improving agent containing PC-SOD thus prepared as an active ingredient, and preferably contains a stabilizer together with PC-SOD.
- a stabilizer is a sugar component.
- the sugar component is not particularly limited as long as it is a pharmaceutically used sugar component, and sucrose is particularly preferable. Therefore, the most preferred COPD improving agent provided by the present invention is a composition containing sucrose together with PC-SOD.
- the sucrose is preferably purified to such an extent that it can be used as a pharmaceutical product.
- sucrose treated with activated carbon is preferably used.
- the blending ratio of PC-SOD and sucrose in the COPD improving agent of the present invention can be appropriately determined according to the dose, the form of the preparation, etc., and is not particularly limited.
- the weight ratio of PC-SOD to sucrose is preferably in the range of about 0.1 / 100 to 80/100, more preferably about 0.4 / 100 to 60/100.
- the COPD improving agent of the present invention does not affect the activity of PC-SOD and does not affect the effect of the preparation, as well as other pharmaceutically active ingredients and commonly used preparation ingredients such as excipients.
- Binders, lubricants, colorants, disintegrants, buffers, isotonic agents, preservatives, soothing agents, and the like can be added.
- the preparation of the COPD improving agent provided by the present invention can be carried out by a commonly known method using PC-SOD and sucrose.
- the PC-SOD used in the pharmaceutical composition of the present invention is preferably in the form of a solution, frozen or lyophilized.
- the COPD improving agent As one aspect of the COPD improving agent provided by the present invention, it can be administered preferably in the form of an injection.
- the injection is preferably in the form of a solution, suspension, emulsion, solid preparation for use, etc., and these preparations should be prepared according to the method described in the Japanese Pharmacopoeia General Rules for Preparations. Can do.
- the COPD improving agent provided by the present invention can be administered in another form, preferably in the form of an inhalant.
- an inhalant means a pharmaceutical composition for reaching the trachea, bronchi, lung, etc., preferably a nasal drop or a composition suitable for nasal or pulmonary administration, particularly pulmonary administration. It is a composition suitable for.
- the above-mentioned PC-SOD can be used as an active ingredient and can be produced in the form of powder, solution or suspension.
- the above-mentioned PC-SOD which is an active ingredient, is used as it is, or additives such as excipients, lubricants, binders, disintegrants, stabilizers, flavoring and flavoring agents. It can manufacture by adding and refine
- PC-SOD is mixed with water or a mixture of water and an auxiliary solvent such as ethanol, propylene glycol, or polyethylene glycol. It can be produced by dissolving or suspending.
- solutions or suspensions can further contain preservatives, solubilizers, buffers, isotonic agents, absorption enhancers, thickeners and the like.
- the inhalant produced as described above is nebulized into a nasal cavity or oral cavity by using a general means in the field of inhalants, for example, a dropper, pipette, cannula or atomizer such as an atomizer or a nebulizer. Or directly into the trachea, bronchi, lungs, etc. If a nebulizer is used, an aerosol in the form of a pressurized bag with a suitable propellant (eg, a chlorofluorocarbon such as dichlorofluoromethane, trichlorofluoromethane or dichlorotetrafluoroethane, or a gas such as carbon dioxide). As a nebulizer or administered using a nebulizer.
- a suitable propellant eg, a chlorofluorocarbon such as dichlorofluoromethane, trichlorofluoromethane or dichlorotetrafluoroethane, or a gas such
- the amount of PC-SOD, which is an active ingredient in the COPD improving agent of the present invention, and the dosage of the preparation vary depending on the preparation method of the preparation, the dosage form, the degree of the target disease, the age of the patient, the body weight, and cannot be generally limited. For example, 0.5 to 100 mg (1500 to 300,000 U) per adult can be exemplified as a clinical amount.
- the number of administrations is not limited in general, but it is also possible to administer once a day or several times a day.
- Test Example 1 Effect of PC-SOD on porcine pancreatic elastase-induced COPD model mice (intravenous administration) [Method] Porcine spleen esterase was administered to 6-8 week old BALB / c mice at 50 ⁇ g via the respiratory tract per mouse to cause lung injury. PC-SOD at each concentration (1.5 and 3.0 kU / kg) was intravenously administered once a day, and after 3 days, the alveolar lavage fluid was collected and the total number of cells was counted. Further, the cells were stained by the Diffquick method, and the number of each inflammatory cell was counted.
- the mouse was euthanized, a section of lung tissue was prepared, H & E staining was performed, and a stained image ( ⁇ 40) was obtained by electron microscopy.
- the mean alveolar diameter (Mean Linear Intercept: ⁇ m) was measured from the H & E stained image.
- [result] 1 The total number of cells in the alveolar lavage fluid is shown in FIG.
- administration of porcine spleen esterase increased the total number of cells and predicted an increase in inflammatory cells.
- PC-SOD since this increase was attenuated by PC-SOD, it was predicted that PC-SOD exerts an anti-inflammatory effect.
- FIGS. 2 shows the results for alveolar macrophages
- FIG. 3 shows the results for neutrophils
- FIG. 4 shows the results for lymphocytes.
- the decrease in inflammatory cells was observed when PC-SOD was administered intravenously at 1.5 and 3.0 kU / kg, and it was found that the anti-inflammatory effect was significantly exhibited. .
- FIG. 5 shows the result of a micrograph of lung tissue stained with H & E
- FIG. 6 shows the result of mean alveolar diameter (Mean Linear Intercept: ⁇ m).
- Test Example 2 Effect of PC-SOD on porcine pancreatic elastase-induced COPD model mice (inhalation administration) [Method] 6-8 week old BALB / c mice were administered 50 ⁇ g of porcine spleen esterase via the respiratory tract per mouse to cause lung injury. An inhalant containing PC-SOD at each concentration (30 and 60 kU / Chamber) was inhaled once a day, and after 3 days, the alveolar lavage fluid was collected and the total number of cells was counted. Further, the cells were stained by the Diffquick method, and the number of each inflammatory cell was counted.
- the mouse was euthanized, a section of lung tissue was prepared, H & E staining was performed, and a stained image ( ⁇ 40) was obtained by electron microscopy.
- the mean alveolar diameter (Mean Linear Intercept: ⁇ m) was measured from the H & E stained image.
- FIG. 11 shows the result of a micrograph of lung tissue stained with H & E
- FIG. 12 shows the result of mean alveolar diameter (Mean Linear Intercept: ⁇ m).
- inhalation (transpulmonary) administration of an inhalant containing PC-SOD of PC-SOD of 30 and 50 kU / Chamber) has an elastase-dependent mean alveolar diameter. It turns out that it suppresses prolongation and suppresses lung injury.
- Formulation Example 1 Intravenous injection PC-SOD 1% (w / w), sucrose 10% (w / w), and benzalkonium chloride 0.05% (w / w) were dissolved in a 5% aqueous xylitol solution. Lyophilized. An intravenous injection preparation was obtained by adding 0.5% carmellose or water for injection separately filled into the resulting freeze-dried preparation.
- Example 2 Inhalant Inhalant solution (1) PC-SOD 1% (w / w), sucrose 10% (w / w) and benzalkonium chloride 0.05% (w / w) are dissolved in a 5% aqueous xylitol solution to prepare an inhalation solution.
- Liquid for inhalation (2) PC-SOD 1% (w / w), sucrose 10% (w / w), benzalkonium chloride 0.05% (w / w), polyethylene glycol 10% (w / w), propylene glycol 20% (w / W), and prepare the inhalation solution with the remaining purified water.
- Powder for inhalation Prepare a powder for inhalation with PC-SOD 5% (w / w) and the remainder sucrose (fine powder).
- the COPD improving agent provided by the present invention contains specific PC-SOD as an active ingredient, and has excellent affinity for cell membranes and the like compared to conventional SOD.
- the ability to eliminate the superoxide anion at the lesion site is high.
- the stability is excellent, and the effect of SOD with a short half-life is continuously exhibited. Due to the effect of SOD, by eliminating active oxygen such as superoxide anion that induces cell damage, these inductions can be effectively suppressed, and as a result, COPD can be effectively improved.
- the value of is tremendous.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Otolaryngology (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
そこで本発明者は、かかる考え方に立脚して、先に提案している細胞親和性の高いレシチン化スーパーオキサイドジスムターゼ(PC-SOD)についてCOPDへの適用を検討した結果、このPC-SODがCOPDの症状改善に極めて効果的であることを確認して、本発明を完成させるに至った。
下記一般式(I):
SOD’(Q-B)m (I)
(式中、SOD’はスーパーオキサイドジスムターゼの残基を表し、Qは化学的架橋を表し、Bはグリセロールの2位に水酸基を有するリゾレシチンにおけるその水酸基の水素原子を除いた残基を表し、mはスーパーオキサイドジスムターゼ1分子に対するリゾレシチンの平均結合数であって、1以上の整数を表す)
で表されるレシチン化スーパーオキサイドジスムターゼを有効成分とすることを特徴とするCOPD改善剤である。
これまで効果的なCOPD改善剤が存在しなかった状況下において、特異的なPC-SODを投与することにより、その症状の改善を行える点で、その医療上の効果は極めて特異的なものである。
SOD’(Q-B)m (I)
(式中、SOD’はスーパーオキサイドジスムターゼの残基を表し、Qは化学的架橋を表し、Bはグリセロールの2位に水酸基を有するリゾレシチンにおけるその水酸基の水素原子を除いた残基を表し、mはスーパーオキサイドジスムターゼ1分子に対するリゾレシチンの平均結合数であって、1以上の整数を表す)
で表すことができる。
したがって、特開平9-117279号公報に記載されるヒトCu/Zn SODの調製は、本明細書の一部を構成し、本発明で使用するPC-SODは、これらのヒトCu/Zn SODを素材として得ることができる。
-O-CH(CH2OR)[CH2OP(O)(O-)(OCH2CH2N+(CH3)3)]
(II)
(式中、Rは脂肪酸残基(アシル基)である)
で表される。
なお、上記化学的架橋の残基においてnとしては2以上の整数であり、好ましくは2~10の整数である。
なお、本発明において1U(ユニット)とは、pH7.8/30℃の条件下でNBT(ニトロブルーテトラゾリウム)を用いてJ. Biol. Chem., vol.244, No.22 6049-6055 (1969) に記載の方法に準じて測定し、NBTの還元速度を50%阻害するPC-SODの酵素量を表す。
かかる吸入剤とは、気管、気管支、肺等へ到達させるための医薬組成物を意味し、好適には、点鼻剤又は経鼻若しくは経肺投与に適した組成物であり、特に経肺投与に適した組成物である。
[方法]
6~8週齢のBALB/cマウスに、ブタ脾臓エステラーゼを、マウス1匹あたり50μg経気道投与し、肺傷害を作成させた。
各濃度(1.5及び3.0kU/kg)のPC-SODを一日一回静脈内投与し、3日後に肺胞洗浄液を回収し、全細胞数をカウントした。
また、細胞をディフクイック法により染色し、各炎症性細胞数をカウントした。
更に、マウスを安楽死させ、肺組織の切片を作成し、H&E染色を行い、電子顕微鏡撮影により染色像(×40)を得た。
そのH&E染色像より、平均肺胞径(Mean Linear Intercept:μm)を測定した。
1.肺胞洗浄液中の全細胞数を図1に示した。
図中の結果から判明するように、ブタ脾臓エステラーゼ投与により、全細胞数は上昇し、炎症性細胞の増加が予測された。また、この上昇はPC-SODにより減弱したことから、PC-SODが抗炎症作用を発揮することが予測された。
2.各炎症性細胞数を図2~図4に示した。
図2は肺胞マクロファージの結果を、図3は好中球の結果を、図4はリンパ球の結果を示した。
図中の結果からも判明するように、PC-SODの1.5及び3.0kU/kg静脈投与で、炎症性細胞の減少が見られ、有意に抗炎症作用を示していることが判明する。
各図中に示した結果からも判明するように、PC-SODの1.5及び3.0kU/kg静脈投与は、エラスターゼ依存の平均肺胞径の延長を抑制し、肺傷害を抑制していることが判明する。
[方法]
6~8週齢のBALB/cマウスに、ブタ脾臓エステラーゼを、マウスあたり50μg経気道投与し、肺傷害を作成させた。
各濃度(30及び60kU/Chamber)のPC-SODを含有する吸入剤を一日一回吸入投与し、3日後に肺胞洗浄液を回収し、全細胞数をカウントした。
また、細胞をディフクイック法により染色し、各炎症性細胞数をカウントした。
更に、マウスを安楽死させ、肺組織の切片を作成し、H&E染色を行い、電子顕微鏡撮影により染色像(×40)を得た。
そのH&E染色像より、平均肺胞径(Mean Linear Intercept:μm)を測定した。
1.肺胞洗浄液中の全細胞数を図7に示した。
図中の結果から判明するように、ブタ脾臓エステラーゼ投与依存によって上昇した全細胞数はPC-SODにより減弱したことから、PC-SODが抗炎症作用を発揮したことが予測された。
2.各炎症性細胞数を図8~図10に示した。
図8は肺胞マクロファージの結果を、図9は好中球の結果を、図10はリンパ球の結果を示した。
図中の結果からも判明するように、PC-SODの30及び50kU/Chamber)のPC-SODを含有する吸入剤の吸入投与(経肺投与)は、有意に抗炎症作用を示していることが判明する。
各図中に示した結果からも判明するように、PC-SODの30及び50kU/Chamber)のPC-SODを含有する吸入剤の吸入(経肺)投与は、エラスターゼ依存の平均肺胞径の延長を抑制し、肺傷害を抑制していることが判明する。
PC-SOD1%(w/w)、シュークロース10%(w/w)、塩化ベンザルコニウム0.05%(w/w)を5%キシリトール水溶液に溶解した後、凍結乾燥した。得られた凍結乾燥剤に、別にバイアル充填した0.5%カルメロースあるいは注射用水を加えることにより静脈注射用剤を得た。
吸入用液剤(1)
PC-SOD1%(w/w)、シュークロース10%(w/w)、塩化ベンザルコニウム0.05%(w/w)を5%キシリトール水溶液に溶解し、吸入用液剤を調製する。
PC-SOD1%(w/w)、シュークロース10%(w/w)、塩化ベンザルコニウム0.05%(w/w)、ポリエチレングリコール10%(w/w)、プロピレングリコール20%(w/w)、残部精製水で吸入用液剤を調製する。
PC-SODが5%(w/w)、残部シュークロース(微細粉末状)で吸入用散剤を調製する。
Claims (13)
- 下記一般式(I):
SOD’(Q-B)m (I)
(式中、SOD’はスーパーオキサイドジスムターゼの残基を表し、Qは化学的架橋を表し、Bはグリセロールの2位に水酸基を有するリゾレシチンにおけるその水酸基の水素原子を除いた残基を表し、mはスーパーオキサイドジスムターゼ1分子に対するリゾレシチンの平均結合数であって、1以上の整数を表す)
で表されるレシチン化スーパーオキサイドジスムターゼを有効成分とすることを特徴とする慢性閉塞性肺疾患改善剤。 - 式(I)において、Qが-C(O)-(CH2)n-C(O)-(式中、nは2以上の整数を表す)であることを特徴とする請求項1に記載の慢性閉塞性肺疾患改善剤。
- SOD’が、ヒトのスーパーオキサイドジスムターゼの残基であることを特徴とする請求項1または2に記載の慢性閉塞性肺疾患改善剤。
- SOD’が、ヒトのスーパーオキサイドジスムターゼのアミノ酸配列における111位のアミノ酸がS-(2-ヒドロキシエチルチオ)システインとなったスーパーオキサイドジスムターゼ修飾体の残基であることを特徴とする請求項1または2に記載の慢性閉塞性肺疾患改善剤。
- スーパーオキサイドジスムターゼが、活性中心に銅と亜鉛を含むスーパーオキサイドジスムターゼであることを特徴とする請求項3または4に記載の慢性閉塞性肺疾患改善剤。
- nが2~10の整数である請求項2ないし5のいずれか1項に記載の慢性閉塞性肺疾患改善剤。
- mが1~12の整数である請求項1ないし6のいずれか1項に記載の慢性閉塞性肺疾患改善剤。
- さらに安定化剤を含有することを特徴とする請求項1ないし7のいずれか1項に記載の慢性閉塞性肺疾患改善剤。
- 安定化剤が、糖であることを特徴とする請求項8に記載の慢性閉塞性肺疾患改善剤。
- 糖が、シュークロースであることを特徴とする請求項9に記載の慢性閉塞性肺疾患改善剤。
- シュークロースが、活性炭処理されたシュークロースであることを特徴とする請求項10に記載の慢性閉塞性肺疾患改善剤。
- 注射剤の形態にあることを特徴とする請求項1に記載の慢性閉塞性肺疾患改善剤。
- 吸入剤の形態にあることを特徴とする請求項1に記載の慢性閉塞性肺疾患改善剤。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010800112435A CN102348465A (zh) | 2009-03-13 | 2010-03-02 | 慢性阻塞性肺疾病改善剂 |
US13/254,242 US20120034202A1 (en) | 2009-03-13 | 2010-03-02 | Ameliorating agent for chronic obstructive pulmonary disease |
EP10750713.9A EP2407176B1 (en) | 2009-03-13 | 2010-03-02 | Ameliorating agent for chronic obstructive pulmonary disease |
CA2755116A CA2755116C (en) | 2009-03-13 | 2010-03-02 | Ameliorating agent for chronic obstructive pulmonary disease |
US14/033,287 US20140023629A1 (en) | 2009-03-13 | 2013-09-20 | Ameliorating agent for chronic obstructive pulmonary disease |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009-061075 | 2009-03-13 | ||
JP2009061075A JP5459827B2 (ja) | 2009-03-13 | 2009-03-13 | 慢性閉塞性肺疾患改善剤 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/254,242 A-371-Of-International US20120034202A1 (en) | 2009-03-13 | 2010-03-02 | Ameliorating agent for chronic obstructive pulmonary disease |
US14/033,287 Continuation US20140023629A1 (en) | 2009-03-13 | 2013-09-20 | Ameliorating agent for chronic obstructive pulmonary disease |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010103959A1 true WO2010103959A1 (ja) | 2010-09-16 |
Family
ID=42728249
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2010/053317 WO2010103959A1 (ja) | 2009-03-13 | 2010-03-02 | 慢性閉塞性肺疾患改善剤 |
Country Status (7)
Country | Link |
---|---|
US (2) | US20120034202A1 (ja) |
EP (1) | EP2407176B1 (ja) |
JP (1) | JP5459827B2 (ja) |
KR (1) | KR101654959B1 (ja) |
CN (2) | CN105126112A (ja) |
CA (1) | CA2755116C (ja) |
WO (1) | WO2010103959A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6731730B2 (ja) * | 2015-01-07 | 2020-07-29 | 東京都公立大学法人 | 抗酸化機能を有するエピジェネティクコントロールキャリアによる慢性閉塞性肺疾患(copd)治療 |
JPWO2017073255A1 (ja) * | 2015-10-29 | 2018-08-16 | 株式会社Lttバイオファーマ | 急性呼吸促迫症候群治療剤 |
EP3970942B1 (en) * | 2020-03-31 | 2024-03-27 | Toray Industries, Inc. | Composite molded article |
BR112023024140A2 (pt) | 2021-05-18 | 2024-02-06 | Ltt Bio Pharma Co Ltd | Composição farmacêutica que compreende uma superóxido dismutase lecitinizada e uso de uma superóxido dismutase lecitinizada para tratar ou prevenir um distúrbio associado com a administração de um agente anticâncer |
Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0654681A (ja) * | 1991-06-07 | 1994-03-01 | L T T Kenkyusho:Kk | レシチン化スーパーオキシドディスムターゼ及びそれを有効成分とする医薬 |
JPH0952843A (ja) | 1995-08-09 | 1997-02-25 | Samu Kenkyusho:Kk | 急性腎不全治療剤 |
JPH0959178A (ja) | 1995-08-24 | 1997-03-04 | Samu Kenkyusho:Kk | 抗ウイルス剤及び抗ウイルス作用増強剤 |
JPH09110717A (ja) | 1995-10-21 | 1997-04-28 | Samu Kenkyusho:Kk | ループス腎炎治療剤 |
JPH09117279A (ja) | 1995-10-25 | 1997-05-06 | Samu Kenkyusho:Kk | レシチン化スーパーオキシドディスムターゼおよびそれを有効成分とする医薬 |
JPH10338645A (ja) | 1997-06-06 | 1998-12-22 | Samu Kenkyusho:Kk | 脳血管障害に伴う機能障害改善剤 |
JP2001002585A (ja) | 1999-06-22 | 2001-01-09 | Ltt Kenkyusho:Kk | レシチン化スーパーオキシドジスムターゼ含有抗線維化剤 |
JP2001064199A (ja) | 1999-06-24 | 2001-03-13 | Ltt Kenkyusho:Kk | レシチン化スーパーオキシドジスムターゼ含有医薬組成物 |
JP2001151695A (ja) | 1999-11-26 | 2001-06-05 | Ltt Institute Co Ltd | アレルギー疾患処置剤 |
JP2006056890A (ja) | 2004-08-19 | 2006-03-02 | Rottapharm Spa | Copdの処置用薬物としてのn−フェニルベンズアミド誘導体 |
JP2006169128A (ja) | 2004-12-13 | 2006-06-29 | Ltt Bio-Pharma Co Ltd | 熱傷治療剤 |
JP2007099201A (ja) | 2005-10-07 | 2007-04-19 | Combi Corp | 幼児用姿勢保持クッション及び該クッションを用いた幼児支持構造 |
JP2008189667A (ja) | 2006-08-25 | 2008-08-21 | Stelic Institute Of Regenerative Medicine | 慢性閉塞性肺疾患改善剤 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60037190T2 (de) * | 1999-06-24 | 2008-03-20 | Ltt Bio-Pharma Co., Ltd. | Medikamentzusammensetzung die lecithin-modifizierte superoxiddismutase enthält |
AU2001248839A1 (en) * | 2000-04-25 | 2001-11-07 | Tomoaki Hoshino | Remedies for interstitial pneumonia, method of constructing animal model of this disease and screening method with the use of the same |
JPWO2008075706A1 (ja) * | 2006-12-19 | 2010-04-15 | 株式会社Lttバイオファーマ | 間質性肺炎治療剤 |
-
2009
- 2009-03-13 JP JP2009061075A patent/JP5459827B2/ja not_active Expired - Fee Related
-
2010
- 2010-03-02 CN CN201510546801.2A patent/CN105126112A/zh active Pending
- 2010-03-02 US US13/254,242 patent/US20120034202A1/en not_active Abandoned
- 2010-03-02 WO PCT/JP2010/053317 patent/WO2010103959A1/ja active Application Filing
- 2010-03-02 CA CA2755116A patent/CA2755116C/en not_active Expired - Fee Related
- 2010-03-02 EP EP10750713.9A patent/EP2407176B1/en not_active Not-in-force
- 2010-03-02 CN CN2010800112435A patent/CN102348465A/zh active Pending
- 2010-03-02 KR KR1020117023925A patent/KR101654959B1/ko active IP Right Grant
-
2013
- 2013-09-20 US US14/033,287 patent/US20140023629A1/en not_active Abandoned
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0654681A (ja) * | 1991-06-07 | 1994-03-01 | L T T Kenkyusho:Kk | レシチン化スーパーオキシドディスムターゼ及びそれを有効成分とする医薬 |
JPH0952843A (ja) | 1995-08-09 | 1997-02-25 | Samu Kenkyusho:Kk | 急性腎不全治療剤 |
JPH0959178A (ja) | 1995-08-24 | 1997-03-04 | Samu Kenkyusho:Kk | 抗ウイルス剤及び抗ウイルス作用増強剤 |
JPH09110717A (ja) | 1995-10-21 | 1997-04-28 | Samu Kenkyusho:Kk | ループス腎炎治療剤 |
JPH09117279A (ja) | 1995-10-25 | 1997-05-06 | Samu Kenkyusho:Kk | レシチン化スーパーオキシドディスムターゼおよびそれを有効成分とする医薬 |
JPH10338645A (ja) | 1997-06-06 | 1998-12-22 | Samu Kenkyusho:Kk | 脳血管障害に伴う機能障害改善剤 |
JP2001002585A (ja) | 1999-06-22 | 2001-01-09 | Ltt Kenkyusho:Kk | レシチン化スーパーオキシドジスムターゼ含有抗線維化剤 |
JP2001064199A (ja) | 1999-06-24 | 2001-03-13 | Ltt Kenkyusho:Kk | レシチン化スーパーオキシドジスムターゼ含有医薬組成物 |
JP2001151695A (ja) | 1999-11-26 | 2001-06-05 | Ltt Institute Co Ltd | アレルギー疾患処置剤 |
JP2006056890A (ja) | 2004-08-19 | 2006-03-02 | Rottapharm Spa | Copdの処置用薬物としてのn−フェニルベンズアミド誘導体 |
JP2006169128A (ja) | 2004-12-13 | 2006-06-29 | Ltt Bio-Pharma Co Ltd | 熱傷治療剤 |
JP2007099201A (ja) | 2005-10-07 | 2007-04-19 | Combi Corp | 幼児用姿勢保持クッション及び該クッションを用いた幼児支持構造 |
JP2008189667A (ja) | 2006-08-25 | 2008-08-21 | Stelic Institute Of Regenerative Medicine | 慢性閉塞性肺疾患改善剤 |
Non-Patent Citations (4)
Title |
---|
ANNUAL REVIEW OF MEDICINE, vol. 40, 1989, pages 411 - 429 |
BARNES, P.J. ET AL.: "Prospects for new drugs for chronic obstructive pulmonary disease", LANCET, vol. 364, no. 9438, 2004, pages 985 - 996, XP005066747 * |
J. BIOL. CHEM., vol. 244, no. 22, 1969, pages 6049 - 6055 |
MASARU SAGAI ET AL.: "Diesel Haiki Biryushi (DEP) no Mouse eno Kikannai Toyo ni yoru Zensoku-yo Byotai no Hatsugen ni Tsuite Tokuni, Kassei Sanso Sansei o Kaishita Eikyo o Chushin to Shite", JOURNAL OF JAPAN SOCIETY OF AIR POLLUTION, vol. 28, no. 4, 1993, pages 220 - 230, XP008167408 * |
Also Published As
Publication number | Publication date |
---|---|
KR20110138372A (ko) | 2011-12-27 |
JP2010215527A (ja) | 2010-09-30 |
JP5459827B2 (ja) | 2014-04-02 |
EP2407176A1 (en) | 2012-01-18 |
CA2755116A1 (en) | 2010-09-16 |
US20140023629A1 (en) | 2014-01-23 |
CA2755116C (en) | 2017-04-18 |
KR101654959B1 (ko) | 2016-09-06 |
CN105126112A (zh) | 2015-12-09 |
CN102348465A (zh) | 2012-02-08 |
EP2407176A4 (en) | 2012-11-28 |
US20120034202A1 (en) | 2012-02-09 |
EP2407176B1 (en) | 2016-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0954283A2 (en) | Formulation and method for treating neoplasms by inhalation | |
JP7089011B2 (ja) | 急性呼吸促迫症候群治療剤 | |
JP2010503731A (ja) | 肺サーファクタント製剤および粘液クリアランスの促進方法 | |
JPH10508602A (ja) | 肺の薬剤デリバリーを促進するための液体フルオロカーボンの使用 | |
JP5459827B2 (ja) | 慢性閉塞性肺疾患改善剤 | |
US20100143321A1 (en) | Therapeutic composition for interstitual pneumonia | |
JPWO2005004914A1 (ja) | NF−κBデコイを含む呼吸器疾患用治療および予防のための薬学的組成物およびその使用方法 | |
EP1225913B1 (en) | Use of nitric oxide for the treatment of airway constriction | |
KR20110094321A (ko) | 수식형 수퍼옥사이드 디스뮤타아제 함유 흡입제 | |
JP2006169128A (ja) | 熱傷治療剤 | |
US20100048621A1 (en) | Medicament for treating chronic obstructive pulmonary disease | |
PT99837A (pt) | Processo para a preparacao de composicoes farmaceuticas contendo interferao alfa e metodo para administracao de interferao alfa por inalacao oral para tratar asma e doencas pulmonares proliferativas nao malignas | |
CN101583373A (zh) | 间质性肺炎治疗剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080011243.5 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10750713 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2755116 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2010750713 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13254242 Country of ref document: US Ref document number: 2010750713 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20117023925 Country of ref document: KR Kind code of ref document: A |